ReviewNature cardiovascular research2026
Valve biology and rheumatic heart disease pathogenesis.
Review in Nature cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Disease Modifying Therapies for Chronic Rheumatic Heart Disease: Promise, Mechanisms, and the Road Ahead.JACC. Asia · 2026Article
- Immune Mechanisms of Heart Valve Development, Homeostasis, and Disease.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rheumatic heart disease (RHD) is an acquired chronic inflammatory disease of the heart valves. Regarded as an autoimmune sequela of Streptococcus pyogenes infection, RHD is triggered by the development of carditis during acute rheumatic fever and persists as chronic rheumatic valvulitis in a proportion of patients with acute rheumatic fever. Permanent valve tissue damage ensues, often leading to heart failure. Effective interventions for established RHD are lacking and valve surgery is currently the only treatment option. The limited number of therapeutic targets for heart valve diseases reflects the complexities of studying the mechanisms underlying early valve pathobiology. However, technological advances now enable in-depth profiling of peripheral blood and valve tissue samples from people with RHD, opening new avenues to interrogate human-specific disease processes. In this Review, we revisit established immunological principles of RHD pathogenesis in light of emerging studies. We also explore both systemic and tissue-centric research gaps to advance our understanding of disease mechanisms and to identify human-relevant therapeutic strategies for RHD.
Indexed as
Identifiers
41807679What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.